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1. Introduction 
Multiple myeloma (MM) is a malignant neoplasm of plasma cells that is characterized by 
the production of pathologic M proteins, bone lesions, kidney disease, hyperviscosity, and 
hypercalcemia. MM occurs more frequently in patients between 50 and 80 years of age, 
with a mean age of 60 years and man are more affected than women (1). Systemic 
symptoms are due to bone pain pathologic fractures, renal failure, hypercalcemia, weight 
loss, fatigue, weakness, fever, thrombocytopenia, neutropenia, diarrhea, orthostatic 
hypotension and infections (2, 3). Initial findings are bone pain in 68% of patients, anemia 
in 62%, renal insufficiency in 55%, hypercalcemia in 30%, hepatomegaly in 21%, and 
splenomegaly in 5%. (4) 
2. Oral and maxillofacial manifestations 
Oral and maxillofacial lesions in patients with multiple myeloma are not uncommon, but 
multiple myeloma is often overlooked. Because the symptoms are many, the disease proves 
difficult to diagnose. Approximately 5 to 30% of myeloma patients have lesions in the jaw. 
Incidental discovery of lesions in the jaw may be the first evidence of this disease. Although 
uncommon, an initial presentation of multiple myeloma may reveal oral or maxillofacial 
symptoms. The oral manifestations of MM are the first sign of the disease in about 14% of 
the patients. (5) 
The patient may experience pain, swelling, numbness of the jaws, epulis formation, or 
unexplained mobility of the teeth. (6 -11)  
More than 30% of patients with MM develop osteolytic lesions in the jaw (9). Osteolytic 
lesions are more frequent in the mandible than in the maxilla, especially in the posterior 
teeth region, ramus and condylar process, presumably because of greater hematopoietic 
activity in these areas. (6,7) The radiographic appearance of the lesions is generally punched 
out osteolytic lesions (60%). In most instances, the lesions appear unassociated with the 
apices of the teeth.(6,12) (Figure 1) From the radiological point of view, MM can exhibit 
three distinct radiographic aspects in the skeletal system, including, in the maxillaries (9):  
1. Bone with no apparent alteration 
2. Multiple radiolucent areas 
3. Generalized bone rarefaction 
4. Osteoporotic alterations 
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Fig. 1. Radiographs showing osteolytic lesions caused by MM in different regions of maxilla 
and mandible. 
Skull lesions are more common than jaw lesions. Multiple radiolucent lesions of varying 
size, with ill-defined margins and a lack of circumferential osteosclerotic activity, should 
suggest this diagnosis (Figure 2). (6) 
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Fig. 2. Lateral Skull view showing multiple punched out radiolucent lesion 
Extraosseous lesions also occur in a significant number of patients (Figure 3) although a 
majority of the lesions are asymptomatic. 
 
Fig. 3. Extraosseous presentations of MM 
Amyloidosis as an additional complication has been reported in 6% to 15% of patients with 
multiple myeloma. Oral manifestations occur in nearly 39% of primary amyloidosis patients in 
which multiple myeloma associated lesions consist a small portion (13-15). Rarely oral 
amyloidosis may be the first symptom of multiple myeloma (16-18). The amyloid deposits in 
oral mucosa of primary amyloidosis patients presents as papules, nodules and plaques(13-
15,19). These lesions may interfere with speech, chewing, swallowing and ability to close 
mouth. Amyloid involvement of oral tissue is rather rare, and the tongue is the most 
encountered subsite (20). Macroglossia, usually seen in primary amyloidosis, occurs in 
approximately 20% of patients (21,22). It seems that almost all secondary amyloidosis 
originates from reactive systematic conditions (23). Even though macroglossia is known to be 
the most common manifestation, mucosal nodules are considered to be more specific signs 
indicative of amyloidosis of the tongue since tongue enlargement can also occur in the absence 
of amyloidosis (19). Amyloid deposition in the salivary glands may cause xerostomia. In late 
stages, lesions may even lead to oropharyngeal blokage (24). Presence of amyloidosis in 
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multiple myeloma patients is usually associated with poor survival. The median survival time 
in these patients is assumed to be about 4 months and death usually occurs as a complication 
of amyloidosis effecting major organ systems (25). Tongue biopsy is an excellent method of 
diagnosis. When a dentist/dental specialist is requested to take a biopsy specimen to detect 
amyloidosis, the specimen must include muscle tissue from the mucobuccal fold or tongue. 
3. Dental management 
Patients in long-term remission can undergo dental treatment, while patients with advanced 
or relapsed disease with reserved prognosis should receive palliative or urgent treatment 
only. Dental treatment should be performed always after consultation with the specialist, as 
it can be modified by certain aspects of the therapy and of the disease prognosis (26). 
It is very important to carry out a detailed history. This should include the diagnosis and 
status of the neoplasia, the nature and duration of previous and ongoing treatment, 
prognosis, comorbid medical conditions, current medications, past dental history, and prior 
history of oral and non-oral infections (27). 
All patients with MM should undergo comprehensive oral and dental evaluation in which is 
important to (26): 
1. Evaluate for presence of petechiae, ecchymosis, gingival hemorrhage, tooth mobility, 
tooth migration, facial pain, and/or paresthesia, indicative of local manifestations of MM. 
2. Evaluate for presence of dental/periodontal disease as a risk factor for development of 
osteonecrosis of the jaw (ONJ) and/or bacteraemia. 
3. Evaluate radiographs (panoramic and periapicals, as indicated) for evidence of 
osteolytic lesions (if detected, refer for further radiographic evaluation) and to 
determine potential risk for developing osteonecrosis of the jaw (ONJ). 
Dental treatment of these patients should be performed before starting the 
chemo/radiotherapy, treating any teeth with pulpal and periapical pathology, periodontal 
abscess, pericoronaritis, gross clinical caries and periodondontal disease. In the case of 
patients scheduled for autologous hematopoietic cell transplant, dental treatment should be 
avoided during the 3 days when stem cells are mobilized and harvested to minimize 
contamination secondary to iatrogenic transient bacteremia (27). 
The main problems in dental treatment of patients with MM are: 
1. Tendency to bleed 
Hemorrhages are the dentist’s major concerns when treating a patient with MM. Bleeding 
may result from several causes, including thrombocytopenia, abnormal platelet function, 
abnormal coagulation, or hyperviscosity. Intraoral bleeding manifests as petechiae and 
ecchymoses, and occasionally hematoma formation. These lesions do not require treatment, 
and large hematomas should not be excised due to risk of hemorrhage. 
For routine operative care where bleeding is not anticipated, treatment can generally be 
provided in even severely thrombocytopenic patients ( ≤ 10,000/ mm3 )without the need for 
transfusions.  
If surgery is necessary, recent results of platelet count, bleeding time, prothrombin time, and 
partial thromboplastin time should be obtained. Depending on the extent of surgery, 
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coordination of platelet transfusion the day of the procedure may be indicated, although 
single tooth extractions can generally be managed by an experienced clinician with localized 
measures even with levels as low as 15,000 cells/mL (27). 
2. Increased risk of infection 
Patients with compromised lymphocyte function or low neutrophil count due to their 
malignancy or secondary to myelosuppressive chemotherapy are prone to newly acquired 
infections and/or exacerbation or reactivation of latent infections (27-29). In many cases the 
clinical presentation of oral infections may be atypical compared to what would normally be 
expected in a healthy patient population. Use of diagnostic tools, including cultures, 
cytological smears, and tissue biopsies, is critical in identifying pathogens and guiding 
appropriate therapies (27). 
a. Dental infections: 
Oral prophylaxis, oral hygiene instruction and elimination of oral sources of infection before 
beginning cancer treatment, can significantly reduce the risk of infectious complications 
(27,29). Odontogenic infections of pulpal and periodontal origin are frequently encountered 
and should be suspected in the presence of orofacial pain, large restorations, gross clinical 
caries, and periapical radiolucency. Dental radiographs must be obtained for any suspected 
odontogenic infection. Endodontically treated teeth with a radiographically adequate seal can 
become symptomatic during severe neutropenia, and while these may be initially managed 
with antibiotics, in most cases extraction is indicated. Similarly, chronic periodontal disease 
can become acutely exacerbated with or without the traditional clinical signs of inflammation 
and swelling. Treatment includes broad-spectrum antibiotics, chlorhexidine rinses, scaling and 
curettage, and extraction of hopeless teeth. Extractions should be performed as early as 
possible prior to beginning therapy to allow maximum healing. Prior to extractions or any 
other invasive procedures the platelet and absolute neutrophils counts must be reviewed and 
appropriate measures taken to minimize risk of complications (27). 
b. Opportunistic infections: 
i. Viral infections: Primary infection or reactivation of herpes family viruses is 
common in these patients, especially during intensive chemotherapy and in the 
context of advanced disease. Herpex simplex virus is the most common viral 
infection in these patients and typically presents as single or multiple painful 
ulcerative lesions that may involve any oral mucosal surface. Varicella-zoster virus 
(VZV) reactivation is less common. Treatments for both infections include 
acyclovir, valacyclovir or famciclovir, the latter appearing to have an advantage in 
preventing post-herpetic neuralgia following VZV infections (27,29). 
ii. Fungal infections: Oropharingeal candidiasis is the most common fungal infection in 
cancer patients. Candidiasis can present as pseudomembranous (the most common), 
erythematous, hyperplastic, or angular cheilitis. Symptoms include generalized 
discomfort, dysgeusia, xerostomia, and burning. Initial episodes can be treated with 
topical azoles or nystatin for 7 to 14 days; in severe cases, systemic therapy should be 
considered with 100 to 200 mg/day of fluconazole or itraconazole for 7 to 14 days or 
long-term for prophylaxis, especially in recurrent cases. In patients with nonhealing 
solitary ulcerations, deep fungal infections (aspergillus, zygomyces, and histoplasma) 
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should be considered, the management of which requires aggressive therapy with 
intravenous azoles, amphotericin B, and the echinocandins (27,29). 
3. Risk of developing osteonecrosis of jaws (ONJ) 
In MM patients treated with radiotherapy or intravenous bisphosphonates there is a risk of 
developing osteonecrosis of jaws. The unique environment of the oral cavity could explain 
why the maxilla and mandible are solely involved. It can be hypothesized that patients who 
have received long-term bisphosphonate therapy may have a compromised blood supply to 
their maxilla and mandible. When dental extractions are performed on this group of 
patients, the open bony wound with a compromised healing ability cannot cope with the 
presence of oral microflora.The extraction wound then becomes infected and progresses into 
osteomyelitis due to the poor healing ability of the tissues. It then develops into 
osteonecrosis. It should be noted that all other bones in the skeleton are well enclosed in the 
soft tissue and thus protected from a resident microflora. (30) 
Preventive recommendations 
A comprehensive recent medical history is essential before commencing any dental 
treatment. Identifying the risk factors in the medical history is mandatory and will help the 
patient’s overall well-being and safety. Patients taking radiotherapy or potent 
bisphosphonates for more than one year, particularly for bone conditions other than 
osteoporosis, and those on concomitant steroids appear to be at highest risk of developing 
ONJ. Other factors that appear to further increase the risks include: residual multiple 
myeloma or another malignancy; hypoproteinemia; renal impairment from disease or 
drugs; and/or chemotherapy. 
The treatment plan for a patient who has been on radiotherapy or bisphosphonate therapy 
should involve restorative dentistry, limited non-surgical periodontics and endodontics to 
control dental decay, periodontal disease and periapical inflammation. Patients who have 
dentures should have well maintained soft liners to minimize trauma to the oral mucosa or 
leave their dentures out. Failing soft liners would be more irritating than a hard but smooth 
denture.  
Extraction and all types of surgery should be avoided. If an extraction is mandatory, for 
example an infected vertically split tooth, then the tooth should be extracted with minimal 
bony damage or exposure. Although there is no research to validate it, prophylactic 
antibiotics and suturing the socket to close the wound are advised. As a novel approach the 
authors have been using orthodontic elastic bands to exfoliate teeth. This results in a slow 
extraction over a few weeks which allows the oral mucosa to migrate down the tooth as it 
exfoliates so there is no open wound.(31,32) 
There are conflicting reports regarding dental implants. Experimental studies show a 
positive effect of bisphosphonates on the bone around implants in experimental animals and 
humans ( 33, 34 35) . Failure of osteintegration in a patient who had successfully integrated 
implants but then commenced on bisphosphonate therapy has been reported.(36) Current 
advice is that placement of implants is best avoided if the patient has serious bone disease 
and are on potent doses. Osteoporotic patients on lower doses need a full informed consent 
before proceeding. Patients on bisphosphonate therapy with existing implants ↓should be 
regularly clinically and radiographically monitored. Increased bone density around the 
implant, similar to that shown around the socket in may occur. If bone pain or loss of 
integrity occurs the superstructure should be removed and the implant left submerged.(36) 
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Bone surgery must be avoided as the bone is exceedingly dense and avascular necrosis may 
occur. 
Full dental assessment and treatment planning should occur prior to the patient 
commencing radiotherapy or bisphosphonate therapy (Table 1). (37) 
 
Table 1. Preventive strategy for OJN 
Therapeutic recommendations 
The first step is to establish the diagnosis if a patient on radiotherapy/bisphosphonate 
therapy presents with a non-healing oral wound. This requires an accurate medical and 
dental history. Patients with diabetes and immunocompromised patients can have delayed 
wound healing. Once the diagnosis of ONJ is made the treating medical practitioner, oral 
and maxillofacial surgeon and dentist need to confer to establish a management plan. At 
present there is no simple single effective treatment for ONJ. (38-42) 
The first approach should be non-surgical with the use of antiseptic mouth rinses and 
antibiotics to prevent or treat secondary infection. Removable appliances lined with a 
periodontal pack that passively cover the bony defect can be inserted to protect the site from 
further trauma and may aid mucosal covering of the exposed bone.(37,42) 
If the exposed bone is painful or there is significant secondary infection, localized surgical 
debridement without primary reconstruction can be considered. Minimal mucoperiosteal 
flap reflection to preserve the blood supply to underlying bone should be used. The problem 
is that the whole skeleton is involved. Resection to a normal bleeding bone margin cannot be 
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undertaken as for osteoradionecrosis. Bone grafting, either as a free graft or by 
microvascular transfer, involves affected bone. There is a risk that there could be two 
problem areas, the donor graft site as well as the recipient jaw site. Major re-section surgery 
should be avoided if at all possible. (38-42) 
In summary, for established cases it is recommended that treatments begin with the 
recognition that palliation and control of secondary infection are the primary goals. Control 
of progression has been obtained in most cases with long-term or intermittent courses of a 
penicillin or second generation cephalosporin, chlorhexidine mouthwash and periodic 
minor debridement of soft-textured sequestrating bone and wound irrigation (Table 2). 
 
*It is probable that this time span is too short. 
**Extreme caution is recommended at this point 
Table 2. Therapeutic management of ONJ 
4. Anemia 
Patients with severe anemia often complain of that they fatigue easily and may not be able 
to tolerate time-consuming dental treatment. 
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Fig. 4. Clinical and radiographic presentations of ONJ 
The need for blood products and the appropriate venue for dental treatment should be 
discussed with the patient’s oncologist, as these patients may require continuous monitoring 
of vital signs and blood counts perioperatively (26). 
5. Corticosteroids treatment 
Patients receiving high-dose systemic corticosteroids may display evidence of secondary 
adrenal insufficiency. Adrenal crises secondary to insufficiency are rare in the dental setting, 
and steroid supplementation before nonsurgical dental procedures is not recommended. 
Steroid supplementation before oral surgery is usually recommended. The amount, 
duration, and venue for supplementation should be determined by both the dental specialist 
performing the procedure and the patient’s oncologist (26). 
6. Secondary malignancy 
Patients treated for MM are at high risk for relapse of primary disease as well as developing 
secondary malignancies. Considering the increased risk of second primary cancer of the 
head and neck in the survivors of MM, and the fact that squamous cell carcinoma is the 
most common second primary solid malignancy after allogeneic hematopoietic cell 
transplant, oral health care professionals play a critical role in the long-term surveillance of 
this patient population (27). 
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7. Specific considerations 
 Patients with renal dysfunction may require modified dosing intervals of 
medications (26). 
 In patients with multiple myeloma, it is important to evaluate for presence of 
hard/soft tissue masses that could indicate deposition of plasma cells and/or light 
chain associated amyloid, and biopsy if necessary (26). 
 Patients with multiple myeloma and significant bone pain, especially in the back, 
may need frequent breaks and may require frequent repositioning during dental 
procedures (26). 
 In patients undergoing orthodontic treatment, the removal of orthodontic 
appliances and delivery of retainers is recommended, as well as the postponement 
of orthodontic treatment until the patient has finished immunosuppressive therapy 
and the risk of hematologic relapse requiring further intervention is reduced 
(43,44). 
Considerations in dental treatment of patients with MM are summarized in table 3. 
Prior to dental treatment During dental treatment 
1. Patients in long-term remission can 
undergo dental treatment, while patients 
with advanced or relapsed disease with 
reserved prognosis should receive 
palliative or urgent treatment only. 
2. Dental treatment should be performed 
always after consultation with the 
specialist 
3. It is important to carry out a detailed 
history, a comprehensive oral and dental 
evaluation and a complete radiographic 
exam. 
4. Dental treatment should be performed 
before starting the chemo/radiotherapy.
1. Bleeding tendency 
2. Increased risk of infection 
3. Risk of developing osteonecrosis of the 
jaw. 
4. Anemia 
5. Corticosteroids treatment 
6. Secondary malignancies 
7. Specific considerations 
Table 3. Considerations in dental treatment of patients with MM 
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